Bristol-Myers Squibb Pharmaceuticals Ltd

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH , UK
Telephone: +44 (0)1895 523 000
Fax: +44 (0)1895 523 010
Medical Information Direct Line: +44 (0)1895 523 740
Medical Information e-mail: medical.information@bms.com
Medical Information Fax: +44 (0)1895 523 677
Summary of Product Characteristics last updated on the eMC: 07/09/2009
SPC Baraclude 0.5 mg and 1.0 mg film coated tablets and Baraclude 0.05mg/ml oral solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   04-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company



2.       QUALITATIVE AND QUANTITATIVE COMPOSITION

 

0.5 mg film‑coated tablets

Each tablet contains 0.5 mg or 1 mg entecavir (as monohydrate).

Excipients: each 0.5 mg tablet contains 120.5 mg lactose.

 

1.0 mg film‑coated tablets

Each tablet contains 1 mg entecavir (as monohydrate).

Excipients: and each 1 mg tablet contains 241 mg lactose.

 

0.05 mg/ml oral solution

Each ml oral solution contains 0.05 mg entecavir (as monohydrate).

Excipient:      650380 mg maltitol liquid/ml
21.5 mg methylhydroxybenzoate/ml
0.2818 mg propylhydroxybenzoate/ml

 

 

4.2     Posology and method of administration

 

Lamivudine-refractory patients (i.e. with evidence of viraemia while on lamivudine or the presence of lamivudine resistance [LVDr] mutations) (see sections 4.4 and 5.1): the recommended dose is 1 mg once daily, which must be taken on an empty stomach (more than 2 hours before or more than 2 hours after a meal) (see sections 4.4, 5.1 and 5.2).

 

4.4     Special warnings and precautions for use

 

Oral Solution

Maltitol: Baraclude oral solution contains maltitol (13 g maltitol liquid per 20 ml dose). Baraclude may have a mild laxative effect. Calorific value 2.3 kcal/g maltitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine. Baraclude   tablets do not contain maltitol and can be taken by patients with fructose intolerance.

 

Parahydroxybenzoates: Baraclude oral solution contains the preservatives methylhydroxybenzoate and propylhydroxybenzoate, that may cause allergic reactions (possibly delayed).

 

4.8     Undesirable effects

 

 

Postmarketing experience: in addition to the adverse drug reactions identified from clinical trials, the following adverse reaction hasreactions have been identified during post-approval use of entecavir.

 

Skin and subcutaneous tissueImmune system disorders:

frequency not known:  rashanaphylactoid reaction

 

 

Skin and subcutaneous tissue disorders:

frequency not known: rash, alopecia

 

4.9     Overdose

 

No caseThere is limited experience of entecavir overdose has been reported in patients. Healthy subjects who received up to 20 mg/day for up to 14 days, and single doses up to 40 mg had no unexpected adverse reactions. If overdose occurs, the patient must be monitored for evidence of toxicity and given standard supportive treatment as necessary.

 

                                                                                                                                                                            

 

5.1     Pharmacodynamic properties

 

(.)

 

In HBV combination assays in cell culture, abacavir, didanosine, lamivudine, stavudine, tenofovir or zidovudine were not antagonistic to the anti-HBV activity of entecavir over a wide range of concentrations. In HIV antiviral assays, entecavir at micromolar concentrations was not antagonistic to the  anti-HIV activity in cell culture of these six NRTIs at > 4 times the Cmax of entecavir.or emtricitabine.

 

(....)

 

Liver biopsy results: 57 patients from the pivotal nucleoside-naive studies 022 (HBeAg positive) and 027 (HBeAg negative) who enrolled in a long-term rollover study were evaluated for long-term liver histology outcomes. The entecavir dosage was 0.5 mg daily in the pivotal studies (mean exposure 85 weeks) and 1 mg daily in the rollover study (mean exposure 177 weeks), and 51 patients in the rollover study initially also received lamivudine (median duration 29 weeks). Of these patients, 55/57 (96%) had histological improvement as previously defined (see above), and 50/57 (88%) had a ≥ 1‑point decrease in Ishak fibrosis score. For patients with baseline Ishak fibrosis score ≥ 2, 25/43 (58%) had a ≥ 2‑point decrease. All (10/10) patients with advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score of 4, 5 or 6) had a ≥ 1 point decrease (median decrease from baseline was 1.5 points). At the time of the long-term biopsy, all patients had HBV DNA < 300 copies/ml and 49/57 (86%) had serum ALT ≤ 1 x ULN. All 57 patients remained positive for HBsAg.

 

 

 

9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

            26th26 June 2006

 

10.     DATE OF REVISION OF THE TEXT

 

          10 February04 August 2009

 

Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu//.

 

http://www.emea.europa.eu/.

 

 

 

 

 

 

 

 

Updated on 09/03/2009 and displayed until 07/09/2009
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   10-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

In section 4.1-  This indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection, nucleoside naive patients and. With respect to patients with lamivudine-refractory hepatitis B (, see sections 4.4 and 5.1).

In section 4.2- reference to see sections 4.4 and 5.1 has been added

In section 4.4-   the section under "Resistance and specific precaution for lamivudine-refractory patient"- has been updated

Insection 5.1- the table showing clinical resistance has been updated to include 5 year resistance data
Updated on 18/09/2008 and displayed until 09/03/2009
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Introduction of new strength
  • Change to section 4.8 - Undesirable Effects
  • Change to section 6.1 - List of Excipients
  • Change to section 6.2 - Incompatibilities
  • Introduction of new pack/pack size
Date of revision of text on the SPC:   22-Aug-2008
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

In section 4.8  -rash  has been added an adverse reaction


Section 6.1- has been updated to include the expients of the Baraclude Oral solution

Section 6.5- has been updated to include the 90 day pack of baraclude film coated tablets  and information about the oral solution container
Updated on 14/02/2008 and displayed until 18/09/2008
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   11/2007
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

chnage to date of revison on SPC
Updated on 10/01/2008 and displayed until 14/02/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01/2008
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Changes to section 4.4, 4.8 and 5.1
Updated on 17/09/2007 and displayed until 10/01/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
Date of revision of text on the SPC:   09/2007
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Changes to section 4.4 and 5.1
Updated on 31/05/2007 and displayed until 17/09/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   05/2007
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Changes to section 4.2 and section 4.4
Updated on 31/07/2006 and displayed until 31/05/2007
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   entecavir monohydrate


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk